Safety Evaluation of the Food Enzyme D-Allulose 3-Epimerase Produced by Genetically Modified Escherichia coli

The enzyme that turns fructose into allulose just cleared its biggest regulatory hurdle. In 2025, the EFSA Panel published a safety assessment of a food enzyme called d-allulose 3-epimerase. The source is a genetically modified strain of Escherichia coli. For formulators and buyers, that means one more tool for allulose production is now backed by a scientific opinion from a major authority.

Background: why this enzyme matters

Allulose is a rare sugar with about 70% of the sweetness of sucrose and almost no calories. It does not spike blood glucose. That makes it attractive for low-sugar formulations. But allulose is scarce in nature. Industrial production relies on enzymatic conversion of bulk fructose.

The enzyme in this assessment works at carbon position 3. It catalyzes the epimerization of D-fructose into D-allulose. In plain terms, it rearranges one hydroxyl group. No harsh chemicals. No high-heat processing. Just a clean biocatalytic step. The enzyme is used in an immobilized form, which means it is attached to a solid support. That design helps processors reuse the catalyst and keep the final product clean.

What the study did

The EFSA Panel evaluated this specific food enzyme as part of the European Union’s food enzyme approval process. The production organism is a genetically modified E. coli. The panel looked at the enzyme’s identity, the production strain, and the conditions of intended use.

The intended application is sugar processing to make specialty carbohydrates, specifically d-allulose. The enzyme does not act on the final food product. It only works during the conversion step. After that, processors can remove or inactivate it.

The assessment did not rely on a single test. It included data on the enzyme’s biochemical properties, the genetic modifications in the host, and potential toxicity or allergenicity. The panel also considered whether the immobilized enzyme could carry over into the finished allulose. Their conclusion was straightforward.

Key findings

The EFSA Panel concluded that this food enzyme does not raise safety concerns under the intended conditions of use. That is the headline. But let’s break down the specifics.

Aspect	Finding
Production organism	Genetically modified Escherichia coli
Catalytic reaction	D-fructose → D-allulose (epimerization at C-3)
Process form	Immobilized enzyme
Intended food use	Sugar processing for specialty carbohydrates
Safety conclusion	No safety concern under intended use

The “no safety concern” wording is standard in EFSA opinions. It does not mean the enzyme is guaranteed safe in every scenario. It means that for the proposed use, the available evidence shows no adverse effects. The panel specifically considered the enzyme’s protein nature. Like other food enzymes, it is expected to be digested or degraded before any significant systemic exposure.

What this means for manufacturers

If you produce or buy allulose, this EFSA opinion gives you regulatory clarity in the EU. An approved enzyme is a prerequisite for commercial use in the European market. The opinion also signals to global buyers that this specific enzyme strain and process have passed a rigorous toxicological review.

For food formulators, the immobilized form is practical. It allows continuous processing. It reduces the risk of enzyme residues in the final syrup. That aligns with clean-label goals. For ingredient buyers, the takeaway is sourcing certainty. You are not just buying an enzyme. You are buying a documented safety dossier that meets high standards.

One caveat: this evaluation applies to this specific enzyme from this specific production strain. Not all allulose 3-epimerases are the same. Different microbial hosts, different genetic modifications, and different purification methods can change the safety profile. Always check the exact strain and the regulatory status of your supplier’s enzyme.

FAQ

Does this mean allulose itself is approved by EFSA?
No. This opinion covers the processing enzyme, not the sweetener. Allulose has a separate regulatory status in the EU. The enzyme approval is one piece of the production chain.

Will the enzyme end up in the final product?
The panel evaluated the enzyme for its intended use in immobilized form. Under good manufacturing practice, the enzyme is retained on the support and does not remain active in the finished allulose.

What should I ask my enzyme supplier?
Ask for the production strain, the immobilization method, and whether they have a favorable EFSA opinion or equivalent regulatory approval. The 2025 opinion gives you a clear reference point.

The science here is clean. A well-characterized enzyme, a defined reaction, and a careful safety review. No loose ends for formulators to worry about. The next step is simply using it.